PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF LC350189, A NOVEL XANTHINE OXIDASE INHIBITOR, IN HEALTHY SUBJECTS

被引：0
|
作者：
Yoon, S. [1 ]
Moon, S. [1 ]
Jang, K. [1 ]
Jang, I. [1 ]
Lim, K. [1 ]
Yu, K. [1 ]
机构：
[1] Seoul Natl Univ, Coll Med & Hosp, Seoul, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S94 / S94
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
    Yoon, Seonghae
    Shin, Donghoon
    Lee, Howard
    Jang, In-Jin
    Yu, Kyung-Sang
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5033 - 5049
  • [2] Pharmacokinetics, pharmacodynamics, and tolerability of LC23-1306, a novel antiplatelet agent, in healthy subjects
    Chang, H. K.
    Shin, D.
    Shin, S.
    Lee, H.
    Chang, H. K.
    Park, H. D.
    Jung, Y.
    Song, M.
    Jang, I. J.
    Yu, K-S
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 891 - 891
  • [3] Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
    Almeida, Luis
    Rocha, Jose Francisco
    Falca, Amilcar
    Nuno Palma, P.
    Loureiro, Ana I.
    Pinto, Roberto
    Bonifacio, Maria Joao
    Wright, Lyndon C.
    Nunes, Teresa
    Soares-da-Silva, Patricio
    [J]. CLINICAL PHARMACOKINETICS, 2013, 52 (02) : 139 - 151
  • [4] Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during the first administration to healthy male subjects
    Nunes, T.
    Rocha, J. -F.
    Pinto, R.
    Machado, R.
    Wright, L.
    Falcao, A.
    Almeida, L.
    Soares-da-Silva, P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 302 - 302
  • [5] PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF NC-2500, A NOVEL XANTHINE OXIDOREDUCTASE INHIBITOR, IN HEALTHY JAPANESE MALE SUBJECTS
    Hirano, M.
    Kobayashi, S.
    Miyayama, E.
    Ohtal, T.
    Yamamoto, M.
    Yamakawa, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1634 - 1635
  • [6] Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects
    Reza Khosravan
    Brian A. Grabowski
    Jing-Tao Wu
    Nancy Joseph-Ridge
    Laurent Vernillet
    [J]. Clinical Pharmacokinetics, 2006, 45 : 821 - 841
  • [7] Pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase, in healthy subjects
    Grabowski, B
    Khosravan, R
    Vernillet, L
    Wu, JT
    Joseph-Ridge, N
    Mulford, D
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1196 - 1196
  • [8] Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects
    Khosravan, Reza
    Grabowski, Brian A.
    Wu, Jing-Tao
    Joseph-Ridge, Nancy
    Vernillet, Laurent
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (08) : 821 - 841
  • [9] Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man
    Yamada, I
    Fukunari, A
    Osajima, T
    Kamezawa, M
    Mori, H
    Iwane, J
    [J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1123 - 1125
  • [10] Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of a Novel Sorbitol Dehydrogenase Inhibitor in Healthy Participants
    Landau, Zohar
    Novotny, Mark J.
    Preston, Gregory M.
    Wright, Kathryn
    Freeman, Thomas
    Dai, Haiqing
    Thompson, John
    Oates, Peter J.
    Calle, Roberto A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (05): : 521 - 530
12345